Evaluation of Hepatic Biochemical Parameters during Antiviral Treatment in COVID-19 Patients

(1) Background: The antiviral treatment for COVID-19 disease started to be largely used in 2020 and has been found to be efficient, although it is not specific for SARS-CoV-2 virus. There were some concerns that it may produce liver damage or other side effects. (2) Methods: The aim of this study wa...

Full description

Bibliographic Details
Published in:	Biology
Main Authors:	Felicia Marc, Corina Moldovan, Anica Hoza, Patricia Restea, Liliana Sachelarie, Laura Ecaterina Romila, Corina Suteu, Dorina Maria Farcas
Format:	Article
Language:	English
Published:	MDPI AG 2021-12-01
Subjects:	coronavirus antivirals hepatic parameters COVID-19
Online Access:	https://www.mdpi.com/2079-7737/11/1/13

Similar Items

Interferon-Free Regimens and Direct-Acting Antiviral Agents for Delta Hepatitis: Are We There Yet?
by: Roxana Nemteanu, et al.
Published: (2023-09-01)

Correlation between Carbonic Anhydrase Isozymes and the Evolution of Myocardial Infarction in Diabetic Patients
by: Sorina Magheru, et al.
Published: (2022-08-01)

The Study of Clinical and Biochemical Parameters in Assessing the Response to the Antiviral Therapy in the Chronic Viral Hepatitis B
by: Alice Elena Ghenea, et al.
Published: (2021-07-01)

New antiviral agents and new treatments on the horizon for the management of viral hepatitis
by: M. Sönmezoğlu
Published: (2011-12-01)

The efficacy of antiviral treatment in chronic hepatitis B patients with hepatic steatosis
by: Danqing Hu, et al.
Published: (2024-04-01)

Chronic Hepatitis C Treatment with New Antiviral Agents
by: Özlem KANDEMİR
Published: (2018-12-01)

Antivirals for Broader Coverage against Human Coronaviruses
by: Mia Outteridge, et al.
Published: (2024-01-01)

Antiviral activity of lactoferrin: a focus on hepatitis C chronic
by: Emille Tejo Viana, et al.
Published: (2024-04-01)

Last Stop Before Exit – Hepatitis C Assembly and Release as Antiviral Drug Targets
by: Birke Andrea Tews, et al.
Published: (2010-08-01)

Hepatitis C Virus and Antiviral Drug Resistance
by: Seungtaek Kim, et al.
Published: (2016-11-01)

Attach importance to antiviral therapy in patients with hepatocellular carcinoma caused by hepatitis virus
by: Shuling Wu, et al.
Published: (2023-01-01)

The effectiveness of different antiviral treatment regimens in patients with chronic hepatitis C infected with genotype 3 virus
by: E.V. Riabokon, et al.
Published: (2018-02-01)

Hepatitis C Virus Infection in Hemodialysis Patients in the Era of Direct-Acting Antiviral Treatment: Observational Study and Narrative Review
by: Ioana Adela Ratiu, et al.
Published: (2024-12-01)

Efficacy of Direct Acting Antivirals (DAA) therapy in patients with recurrent hepatitis C after liver and kidney transplantation: a cross-sectional study
by: Mehdi Kashani, et al.
Published: (2024-10-01)

Antiviral effect of the viroporin inhibitors against Taiwan isolates of infectious bronchitis virus (IBV)
by: Mikael Cristofer Sitinjak, et al.
Published: (2024-11-01)

Editorial: Plant products for antiviral therapeutics
by: Anirban Mandal, et al.
Published: (2022-10-01)

Antiviral Treatment of Chronic Hepatitis B Virus (HBV) Infections
by: Erik De Clercq, et al.
Published: (2010-05-01)

Direct-acting Antiviral Agents Resistance-associated Polymorphisms in Chinese Treatment-naÏve Patients Infected with Genotype 1b Hepatitis C Virus
by: Ye Wang, et al.
Published: (2015-01-01)

Salsolinol-Containing <i>Senna silvestris</i> Exerts Antiviral Activity Against Hepatitis B Virus
by: Alberto Quintero, et al.
Published: (2025-08-01)

The mammalian SKI complex is a broad-spectrum antiviral drug target that upregulates cellular cholesterol to inhibit viral replication
by: Stuart Weston, et al.
Published: (2025-10-01)

Momentum towards simplifying and expanding treatment for chronic hepatitis B: The body of evidence continues to grow: Editorial on “Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TORCH-B trial”
by: Robert J. Wong
Published: (2025-04-01)

EFFECT OF ANTIVIRAL THERAPY ON CARDIOHEMODYNAMIC INDICATORS IN PATIENTS WITH CHRONIC VIRAL HEPATITIS AND LIVER CIRRHOSIS
by: M. V. Chistyakova, et al.
Published: (2017-01-01)

Efficiency of Antiviral Therapy for Recurrence of Chronic Hepatitis C in Patients Undergoing Liver Transplantation
by: A. A. Sukhoruk, et al.
Published: (2014-09-01)

Are There Still Difficult-to-Treat Patients with Chronic Hepatitis C in the Era of Direct-Acting Antivirals?
by: Paweł Pabjan, et al.
Published: (2022-01-01)

Impact of hepatic steatosis on the efficacy of antiviral treatment for chronic hepatitis B and the establishment of predictive model: a cohort study
by: Guanghui Ren, et al.
Published: (2025-02-01)

Hepatitis B Management in the Middle East: A Narrative Review of Current Antiviral Treatments
by: Hannah Beck, et al.
Published: (2024-09-01)

Adverse Effects of Combined Antiviral Therapy of Chronic Hepatitis C Virus and Methods for It’s Correction
by: Y. M. Ambalov, et al.
Published: (2011-09-01)

Cardioprotective effect of antiviral therapy among hepatitis C infected patients: A meta-analysis
by: Vikash Jaiswal, et al.
Published: (2023-12-01)

Direct-Acting Antiviral Agents in Prevention of Maternal–Fetal Transmission of Hepatitis C Virus in Pregnancy
by: Christopher Hartley, et al.
Published: (2024-06-01)

Chronic viral hepatitis С. Effectiveness of antiviral therapy. The WHO methodical recommendations (literature review)
by: V.I. Trykhlib
Published: (2020-02-01)

Iron metabolism in chronic hepatitis C patients on antiviral treatment
by: K. V. Zhdanov, et al.
Published: (2014-09-01)

POSSIBILITIES OF HEPATITIS C ANTIVIRAL TREATMENT IN LIVER TRANSPLANT RECIPIENTS
by: V. E. Syutkin, et al.
Published: (2011-06-01)

Maternal hepatitis B e antigen can be an indicator for antiviral prophylaxis of perinatal transmission of hepatitis B virus
by: Ying Lu, et al.
Published: (2021-01-01)

Antiviral therapy for chronic hepatitis C: is there a time to change existing standards?
by: D. T. Abdurakhmanov
Published: (2009-02-01)

Hepatic Steatosis Index in the Detection of Fatty Liver in Patients with Chronic Hepatitis B Receiving Antiviral Therapy
by: Jin Won Chang, et al.
Published: (2021-01-01)

Direct-Acting Antiviral Agents for Hepatitis C Virus Infection—From Drug Discovery to Successful Implementation in Clinical Practice
by: Christopher Dietz, et al.
Published: (2022-06-01)

Predictive Value of Antiviral Effects in the Development of Hepatocellular Carcinoma in the General Korean Population with Chronic Hepatitis B
by: Jae-Jun Shim, et al.
Published: (2016-11-01)

Efficacy of antiviral therapy in the treatment of severe forms of acute hepatitis B
by: E. V. Esaulenko, et al.
Published: (2016-02-01)

Effects of hepatitis B virus infection and antiviral therapy on the clinical prognosis of nasopharyngeal carcinoma
by: Jing‐Jin Weng, et al.
Published: (2020-01-01)

Assessment and Management of the Dermatological Side Effects of Direct-Acting Antiviral Agent Groups Used in the Treatment of Hepatitis C: A Prospective Study
by: Senay Agirgol, et al.
Published: (2021-06-01)